文献速递前列腺癌

恩扎卢胺治疗转移性激素敏感性前列腺癌在<75岁与≥75岁患者中的临床结局:ARCHES事后分析

Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
PubMed 文献 · Eur Urol Oncol · 2023-12-09

ARCHES试验事后分析纳入1150例转移性激素敏感性前列腺癌(mHSPC)男性,比较<75岁与≥75岁患者接受恩扎卢胺(160 mg/d)联合雄激素剥夺治疗(ADT)或安慰剂联合ADT的结局。恩扎卢胺改善两个年龄组的总生存期(OS)且耐受性总体良好,但≥75岁组剂量中断和治疗中出现的不良事件更频繁;事后分析和小样本量限制确定性结论。

要点

  • 恩扎卢胺联合ADT改善<75岁(HR 0.61)和≥75岁(HR 0.76)患者的OS。
  • ≥75岁患者剂量中断(20.2% vs 10.9%)和治疗中出现的不良事件(95.2% vs 89.1%)更频繁。
  • 事后分析和小样本量限制确定性结论。

核心结论

  • 恩扎卢胺联合ADT改善疗效结局且总体耐受性良好,尽管老年患者治疗暴露时间更短,表明恩扎卢胺对<75岁和≥75岁的mHSPC患者均有 utility。

研究设计与样本

  • multinational、双盲、随机、安慰剂对照的3期ARCHES试验的事后分析,纳入1150例mHSPC男性,中位随访时间:<75岁组44.6个月,≥75岁组44.3个月。
  • 随机1:1接受恩扎卢胺(160 mg/d)联合ADT或安慰剂联合ADT,按疾病体积和既往多西他赛使用分层。

主要发现

  • OS:<75岁 vs ≥75岁,恩扎卢胺联合ADT组HR 0.66(95%CI 0.47-0.91,p=0.02);安慰剂联合ADT组HR 0.81(95%CI 0.60-1.09,p=0.13)。
  • rPFS:<75岁 vs ≥75岁,恩扎卢胺联合ADT组HR 0.78(95%CI 0.58-1.04,p=0.12);安慰剂联合ADT组HR 0.98(95%CI 0.74-1.30,p=0.007)。
  • 恩扎卢胺改善OS:<75岁组HR 0.61(95%CI 0.47-0.79),≥75岁组HR 0.76(95%CI 0.54-1.09)。
  • ≥75岁 vs <75岁患者剂量中断更频繁(20.2% vs 10.9%),治疗中出现的不良事件更频繁(95.2% vs 89.1%)。

关键数值与推荐

  • 恩扎卢胺160 mg/d联合ADT。
  • 随机1:1,按疾病体积和既往多西他赛使用分层。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 事后分析和小样本量妨碍确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In ARCHES, treatment intensification of androgen deprivation therapy (ADT) with enzalutamide versus placebo improved clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Understanding the benefits and tolerability of enzalutamide for men aged ≥75 yr may inform disease management. OBJECTIVE: To determine whether age is associated with clinical outcomes in mHSPC. DESIGN, SETTING, AND PARTICIPANTS: A post hoc analysis of the multinational, double-blind, randomized, placebo-controlled, phase 3 ARCHES trial in 1150 men with mHSPC (median follow-up [mo]: <75 yr, 44.6; ≥75 yr, 44.3) was performed. INTERVENTION: Randomization 1:1 to enzalutamide (160 mg/d) plus ADT or placebo plus ADT; stratification by disease volume and prior docetaxel use. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS), radiographic progression-free survival (rPFS), safety, and other secondary endpoints were compared between age groups (<75 and ≥75 yr) and treatment arms (Cox proportional hazard models). RESULTS AND LIMITATIONS: Men aged <75 versus ≥75 yr had longer OS (enzalutamide plus ADT: hazard ratio [HR] 0.66; 95% confidence interval [CI] 0.47-0.91; p = 0.02; placebo plus ADT: HR 0.81; 95% CI 0.60-1.09; p = 0.13) and rPFS (enzalutamide plus ADT: HR 0.78; 95% CI 0.58-1.04; p = 0.12; placebo plus ADT: HR 0.98; 95% CI 0.74-1.30; p = 0.007). Enzalutamide improved OS (<75 yr: HR 0.61; 95% CI 0.47-0.79; ≥75 yr: HR 0.76; 95% CI 0.54-1.09) and secondary efficacy endpoints without evidence of statistical heterogeneity, and was generally well tolerated in both age groups, with minimal quality-of-life impact. Older versus younger patients experienced more frequent dose interruptions (20.2% vs 10.9%) and treatment-emergent adverse events (95.2% vs 89.1%). Post hoc examination and small sample size preclude definitive conclusions. CONCLUSIONS: Enzalutamide plus ADT improved efficacy outcomes and was generally well tolerated despite shorter treatment exposure in older patients, indicating enzalutamide's utility in patients with mHSPC aged <75 and ≥75 yr. PATIENT SUMMARY: Enzalutamide is a drug approved to treat men with prostate cancer. In this report, we compared patients aged <75 and ≥75 yr treated with enzalutamide plus androgen deprivation therapy to determine whether age affected how long they lived without the cancer spreading to other parts of their body. We found that, although younger patients had more favorable survival outcomes, enzalutamide was associated with longer survival and reduced disease spread in both age groups.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gomez-Veiga F, Szmulewitz RZ, Holzbeierlein J, et al. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis. Eur Urol Oncol. 2023. PMID: 38072761. doi:10.1016/j.euo.2023.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。